[ad_1]
TORONTO, May 18, 2022 /PRNewswire/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE:BRAX) (OTC:BRAXF) (FWB: 4960) is pleased to announce that its CEO, Dr. Roger McIntyre has been invited to speak at the American Psychiatric Association Annual Meeting in New Orleans May 21, 2022.
Dr. McIntyre will participate in two discussions addressing members of the American Psychiatric Association.
The first discussion titled – Ketamine and Esketamine for Treatment-Resistant Depression Synthesizing Scientific Data and Clinical Application will include a review of the International Guidelines on Ketamine and Implementation led by Dr. McIntyre, published in the American Journal of Psychiatry in May 2021. The presentation will also cover real-world data (RWD) with respect to efficacy, safety, and tolerability of ketamine treatment in adults with mood disorders.
The second discussion titled – Treatment Resistant Depression: Current and…
Full story available on Benzinga.com
[ad_2]
Source link
